www.klinickafarmakologie.cz / Klin Farmakol Farm. 2025;39(2):77-83 / KLINICKÁ FARMAKOLOGIE A FARMACIE 83 HLAVNÍ TÉMA Bezpečnost biologické a cílené léčby v revmatologii 24. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64(9):3043-3051. 25. Eshwar V, Kamath A. Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database. Sci Rep. 2024;14(1):1222. 26. Davidson L, van den Reek JMPA, Bruno M, et al. Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources. Lancet Reg Health Eur. 2021;13:100266. 27. Alsakarneh S, Al Ta’ani O, Aburumman R, et al. Risk of de novo inflammatory bowel disease in patients with psoriasis and psoriatic arthritis treated with IL-17A inhibitors: a population-based Study. Aliment Pharmacol Ther 2025 Apr 7. doi: 10.1111/apt.70139. Epub ahead of print. 28. Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81-89.e5. 29. Wu S, Xu Y, Yang L, Guo L, Jiang X. Short-term risk and longterm incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Front Immunol. 2023;14:1294416. 30. Huang PF, Huang TY, Cheng YC, et al. Clinical insights into IL-23 inhibition: risankizumab for Crohn’s disease through a systematic review and meta-analysis of randomized controlled trials. Therap Adv Gastroenterol. 2025;18:17562848251338743. 31. Long M, Danese S, Ott E, et al. Safety of ustekinumab across approved adult indications: pooled safety analysis in Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis through up to 5 years. Abstract. Am J Gastroenterol. 2021;116():p S441. 32. Liu R, Li Z, Ye L, et al. Risk of tuberculosis and hepatitis B reactivation in patients with Crohn’s disease on ustekinumab: a nationwide real-world study. Inflamm Bowel Dis. 2024;30(1):45-52. 33. Honap S, Irving PM, Samaan MA. Ustekinumab-induced inflammatory demyelinating polyneuropathy in a patient with ulcerative colitis. J Crohns Colitis 2023;17(1):144-145. 34. Merrill JT, Ginzler EM, Wallace DJ, et al. LBSL02/99 Study Group. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(10):3364-3373. 35. Xie W, Huang H, Zhan S, et al. Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials. Lupus Sci Med. 2021;8(1):e000534. 36. Kim SS, Kirou KA, Erkan D. Belimumab in systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis. 2012;3(1):11-23. 37. Tummala R, Abreu G, Pineda L, et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med. 2021;8(1):e000464. 38. McHugh J. Long-term anifrolumab safe in SLE. Nat Rev Rheumatol. 2023;19(2):64. 39. Alves C, Penedones A, Mendes D, Marques FB. The Risk of Infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. J Clin Rheumatol. 2022;28(2):e407-e414. 40. Szekanecz Z, Buch MH, Charles-Schoeman C, et al. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol. 2024;20(2):101-115. Připravujeme do Klinické farmakologie a farmacie HLAVNÍ TÉMA – Betablokátory v kardiologii PŮVODNÍ PRÁCE Retrospektívna analýza krvácavých príhod a extrémnych INR v populácii zosnulých pacientov PŘEHLEDOVÉ ČLÁNKY Léčba polymorbidních pacientů s roztroušenou sklerózou Současná farmakoterapie neuropatické bolesti Léčiva ze skupiny ARTA a jejich lékové interakce se zaměřením na antikoagulancia KAZUISTIKA Farmakokinetické interakce klozapinu a olanzapinu: kazuistiky lékových změn při inhibici CYP1A2 …a spoustu dalších zajímavých témat… 20253 ▼ VYCHÁZÍ V ŘÍJNU
RkJQdWJsaXNoZXIy NDA4Mjc=